Stockhead on MSN2 天
Rare opportunities – ASX health stocks tackling unmet medical needs
Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally. ... Read ...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...
manilatimes16 小时
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention ...
Pharmabiz10 小时
US FDA grants fast track designation to NKGen Biotech’s natural killer cell therapy ...
US FDA grants fast track designation to NKGen Biotech’s natural killer cell therapy, troculeucel to treat moderate Alzheimer’s disease: Santa Ana, California Saturday, Februar ...
Bavarian Nordic A/S: Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for ...
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...
Northern Territory News3 天
Rare opportunities – ASX health stocks tackling unmet medical needs
"The FDA is also showing a willingness to look ... a compelling opportunity to bring breakthrough therapies for unmet medical needs to market. Here are some biotechs leading the charge in rare ...
Benzinga.com3 天
Following Positive Phase 2 Results And Orphan Drug Designation, Biodexa's FAP Drug Receives ...
The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions where there is an unmet medical need. FAP, an inherited ...